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A B S T R A C T
Background
Delayed fracture healing causes substantial disability and usually requires additional surgical
treatments. Pharmacologic management to improve fracture repair would substantially
improve patient outcome. The signaling pathways regulating bone healing are beginning to be
unraveled, and they provide clues into pharmacologic management. The b-catenin signaling
pathway, which activates T cell factor (TCF)-dependent transcription, has emerged as a key
regulator in embryonic skeletogenesis, positively regulating osteoblasts. However, its role in
bone repair is unknown. The goal of this study was to explore the role of b-catenin signaling in
bone repair.
Methods and Findings
Western blot analysis showed significant up-regulation of b-catenin during the bone healing
process. Using a b-Gal activity assay to observe activation during healing of tibia fractures in a
transgenic mouse model expressing a TCF reporter, we found that b-catenin-mediated, TCF-
dependent transcription was activated in both bone and cartilage formation during fracture
repair. Using reverse transcription-PCR, we observed that several WNT ligands were expressed
during fracture repair. Treatment with DKK1 (an antagonist of WNT/b-catenin pathway)
inhibited b-catenin signaling and the healing process, suggesting that WNT ligands regulate b-
catenin. Healing was significantly repressed in mice conditionally expressing either null or
stabilized b-catenin alleles induced by an adenovirus expressing Cre recombinase. Fracture
repair was also inhibited in mice expressing osteoblast-specific b-catenin null alleles. In stark
contrast, there was dramatically enhanced bone healing in mice expressing an activated form
of b-catenin, whose expression was restricted to osteoblasts. Treating mice with lithium
activated b-catenin in the healing fracture, but healing was enhanced only when treatment was
started subsequent to the fracture.
Conclusions
These results demonstrate that b-catenin functions differently at different stages of fracture
repair. In early stages, precise regulation of b-catenin is required for pluripotent mesenchymal
cells to differentiate to either osteoblasts or chondrocytes. Once these undifferentiated cells
have become committed to the osteoblast lineage, b-catenin positively regulates osteoblasts.
This is a different function for b-catenin than has previously been reported during
development. Activation of b-catenin by lithium treatment has potential to improve fracture
healing, but only when utilized in later phases of repair, after mesenchymal cells have become
committed to the osteoblast lineage.
The Editors’ Summary of this article follows the references.
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Introduction
Fracture healing is a complex regenerative process
initiated in response to injury, which in the optimal case
results in restoration of skeletal function. In the initial phase
of fracture repair, undifferentiated mesenchymal cells ag-
gregate at the site of injury, proliferate, and differentiate,
presumably in response to growth factors produced by the
injured tissues [1]. This process involves both intramembra-
nous and endochondral ossiﬁcation. Intramembranous ossi-
ﬁcation involves the formation of bone directly from
committed osteoprogenitor cells and undifferentiated mes-
enchymal cells that reside in the periosteum, resulting in hard
callus formation [2,3]. During endochondral ossiﬁcation,
mesenchymal cells differentiate into chondrocytes, producing
cartilaginous matrix, which then undergoes calciﬁcation and
eventually is replaced by bone. The formation of primary
bone is followed by extensive remodeling until the damaged
skeletal element regains original shape and size. These
processes are reminiscent of embryonic bone development,
suggesting that fracture repair recapitulates normal bone
development [4–6]. When fracture healing is impaired,
osteoblastic differentiation is inhibited, and undifferentiated
mesenchymal tissue remains at the fracture site. In patients,
this outcome results in delayed union, or nonunion, usually
requiring additional surgery for successful fracture healing.
In certain surgeries, such as spinal fusion surgery or total
joint replacement, a lack of bone ingrowths results in a failed
outcome and the need for additional surgery. A pharmaco-
logic adjunct to improve bone healing has the potential to
avoid the need for additional surgery in these cases,
improving patient outcomes.
b-catenin signaling has emerged as a key regulator of
embryonic bone development [7,8]. Secreted WNT ligands
and antagonists of WNT signaling bind to the transmembrane
receptors including low-density lipoprotein jureceptor-re-
lated protein 5/6 (LRP5/6) and frizzled (FZ) to regulate the
WNT pathway. WNT signaling activation produces a cyto-
plasmic signaling cascade leading to the transcriptional
regulation of gene expression, cytoskeletal reorganization,
and calcium ﬂux [9]. Signaling through the canonical WNT
pathway is initiated by the binding of appropriate WNT
ligands to the FZs and LRP5/6 co-receptor. In the absence of
appropriate WNT ligands, b-catenin is targeted for phos-
phorylation, ubiquitination and proteosomal degradation by
a multi-protein complex comprising glycogen synthase kinase
3 beta (GSK3b), adenomatous polyposis coli, and axin [10–12].
In the presence of an appropriate WNT ligand, this multi-
protein complex is dissociated by dishevelled (DVL), an
intracellular mediator that plays a central role in transducing
the signal from the receptor complex, leading to the
activation of b-catenin [13]. Hence, b-catenin cannot be
targeted for degradation and translocates to the nucleus,
where in concert with members of the T cell factor/lymphoid
enhancer factor (TCF/LEF) family, activates the transcription
of a wide range of genes. During embryonic skeletogenesis,
inhibition of b-catenin signaling can block osteoblast differ-
entiation and shift pluripotent mesenchymal cells to develop
a chondroblastic phenotype [14,15]. b-catenin signaling also
can regulate bone mass, and its activation results in increased
bone density [16–18].
Although the histology and general mechanism of fracture
repair are clear and well established, much remains to be
understood about the process of bone healing, particularly at
the molecular signaling level. Based on a microarray analysis,
it was found that WNT pathway members are expressed
during fracture repair [19]. DVL is expressed during fracture
repair and when blocked using small interfering RNAs
(siRNAs), inhibits both proliferation and differentiation of
chondrocytes [20]. WNT1-induced secreted protein 1 (WISP1), a
WNT target gene, is also expressed during fracture healing,
and overexpression of this gene increases proliferation but
decreases the differentiation in a chondrocytic cell line [21].
We previously reported that b-catenin regulates wound size
during dermal repair [22], and that oral lithium treatment
could be used to activate b-catenin signaling and to increase
the size of healing cutaneous wounds [23]. Based on these
ﬁndings, it is likely that b-catenin plays a role in fracture
repair. In this study, we aimed at investigating how b-catenin
signaling functions during fracture healing, and to test for the
effect of lithium treatment. Since lithium is a pharmacologic
agent already approved for use in patients, this approach
could be developed into a novel therapy to improve bone
healing.
Methods
Ad-DKK1 and Ad-Cre
Dickkopf 1 (DKK1) is a secreted protein that binds to LRP5/
6 and Kremen proteins, blocking canonical WNT signaling.
An adenovirus harboring murine DKK1 cDNA with a C-
terminal His6 and Flag epitope tags (Ad-DKK1) was gener-
ated and utilized as previously described [24]. Cre recombi-
nase expression was driven by a CMV promoter in an
adenovirus construct (Ad-Cre) generated and utilized as
previously described [22]. The same adenovirus expressing
GFP was utilized as a control. Ad-Cre’s ability to cause
recombination was assessed using reporter mice as we
previously described [22]; it resulted in recombination in
roughly 75% of cells.
Transgenic Mice
Catnbtm2Kem mice [25] possess loxP sites located in introns 1
and 6 of the gene encoding b-catenin, resulting in a null allele
when treated with a Cre recombinase. Catnblox(ex3) mice [26]
contain loxP sequences ﬂanking exon 3, and when subjected
to Cre recombinase, results in the expression of a fully
functional but stabilized b-catenin protein. TCF reporter
mice [22] contain a LacZ gene downstream of a c-fos minimal
promoter and three consensus TCF-binding motifs. Mice
expressing osteoblast-speciﬁc b-catenin null alleles, a1(I)-
Catnbnull, were generated by mating a1(I)-Cre mice [27] with
Catnbtm2Kem animals, and mice expressing osteoblast-speciﬁc
b-catenin stabilized alleles, a1(I)-Catnbstab, were generated by
mating a1(I)-Cre mice with Catnblox(ex3) mice. a1(I)-Cre mice
express the Cre recombinase at high levels in cells committed
to the osteoblast lineage. Activation of the conditional alleles
was conﬁrmed by Western blot analysis and by using a Cre-
reporter mouse as previously reported [25–27].
Generation of Fractures
All animal procedures were reviewed and approved by the
animal care committee of the Hospital for Sick Children in
Toronto. Male mice aged 12 wk were utilized for this study. A
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Figure 1. b-Catenin-Mediated TCF-Dependent Transcription Is Activated during Fracture Healing
(A) Western blot analysis at different time points shows that b-catenin is elevated throughout healing in mice.
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stabilized fracture was generated as previously reported with
minor modiﬁcations [28]. Brieﬂy, a small incision was made
on the dorsolateral side of the thigh and was extended over
the knee region. A longitudinal incision was made in the
patellar tendon, and a 0.5 mm hole was drilled above the tibia
tuberosity. Intramedullary ﬁxation was made by placing an
Anticorro insect pin (Fine Science Tools, http://www.
ﬁnescience.com/) in the marrow space. A fracture was then
made by cutting the shaft of tibia. Previous data show that a
fracture generated in this manner heals through both
endochondral and intramembranous ossiﬁcation [28,29].
For virus treatment, Ad-DKK1, Ad-Cre, or Ad-GFP at a
dosage of 109 pfu per mouse was mixed with Matrigel (BD
Biosciences, http://www.bdbiosciences.com/) and injected into
the fracture site using a microsyringe. For mice treated with
lithium, sterile 0.6 M LiCl (or 0.6 M NaCl as a control) was
added to the drinking water leading to a ﬁnal concentration
of 0.02 M. This oral dosage (;200 mg/kg per day, a dose giving
plasma levels comparable with level used to treat humans
with bipolar illness), previously reported to be effective in
mice [30,31], was administered either 2 wk prior to, or 4 d
after fracture. The animals were allowed free, unrestricted
weight bearing in cages after recovery from anesthesia. At
different time points (3, 4, 7, 14, and 21 d) after the fracture,
mice were sacriﬁced and fracture callus was harvested for
further analysis. At least ﬁve animals at each time point for
each experimental condition were studied.
Evaluation of Fracture Healing
Animals were examined using Faxitron MX20 X-ray system
(Faxitron X-ray Corporation, http://www.faxitron.com/) for
radiographic appearance, and for quantitative analysis of the
bone mineral density at the fracture site using the Lunar PIXI
Small Animal Bone Densitometer (http://www.gehealthcare.
com/). For histological analysis, the tissue at the fracture site
was harvested, ﬁxed in 4% paraformaldehyde, decalciﬁed in
20% EDTA (pH 7.4), and embedded in parafﬁn. Sections 10
lm thick were prepared and stained with hematoxylin–eosin
(HE) and safranin O (SO). For histomorphometric measure-
ments, an average of ten tissue sections was used to determine
callus parameters. An analysis image window, measuring 1.6
mm2, was established for evaluation of cartilage or bone
volume as a percentage of total callus tissue volume,
trabecular thickness (lm), trabecular number (per mm), and
trabecular separation (lm). The radiographs, bone mineral
density, and histological parameters of the cartilage and bone
were evaluated in a blinded manner by an independent
investigator. At least four animals were analyzed for each
group for histological and radiographic parameters. For LacZ
staining, samples were ﬁxed in 4% paraformaldehyde and
stained as previously described [32]. Samples were then
decalciﬁed in 20% EDTA, and embedded in parafﬁn. Sections
were counterstained with Neutral Red.
Reverse Transcription PCR and Western Blot
Total RNA and protein were isolated from the fracture
site, which encompassed the entire callus and less than 2 mm
of adjacent bone. This area corresponds to approximately
those bounded by the lines indicating the proximal and distal
aspect of the fracture callous in the low-magniﬁcation
histological images of the fractures. Quantitative reverse
transcription PCT (RT-PCR) was performed as previously
described [32], with primers listed in Table S1. Expression
was compared to b-2 macroglobin as a ‘‘housekeeping’’
control. All experiments were performed in triplicate.
Western blot analysis was performed using select antibodies
detected using horseradish peroxidase-conjugated secondary
antibody and the ECL chemiluminescence detection system
(Amersham, http://www.gelifesciences.com/). Relative expres-
sion levels were quantiﬁed by densitometry using AlphaEa-
seFC software (Alpha Innotech, http://www.alphainnotech.
com/). Speciﬁc antibodies utilized in this work are listed in
the Table S2.
Human Fracture Sample
Samples from healing fractures from three patients under-
going corrective surgery for a fracture malunion, two
performed 3 wk following the initial fracture and one
performed 3 mo following the initial fracture, were cryopre-
served as soon as possible after surgery. The patients gave
written informed consent to remove fracture samples. These
samples were analyzed by Western blot in an identical
manner to the mouse studies.
Statistical Analyses
Data were expressed as mean 6 standard deviation.
Statistical differences were calculated using Student t test. A
minimum of four animals were analyzed for each group for
histological and radiographic parameters. A p-value below
0.05 was considered statistically signiﬁcant.
Results
b-Catenin Signaling Is Activated during Fracture Healing
To determine the protein level of b-catenin during fracture
healing, we performed Western blot analysis on protein from
the healing callus at different time periods in TCF reporter
mice with stabilized tibia fractures. Previous studies show that
these murine fractures heal through intramembranous and
endochondral ossiﬁcation by a mechanism similar to that in
normal human fracture repair [28,29].
(B) b-catenin is also increased during human fracture healing.
(C–T) LacZ staining for TCF-dependent transcriptional activity in intact tibia (C–E); at 3 d following the tibia fracture (F–H); at 9 d following the fracture
(I–K); at 2 wk following fracture (L–N); at 3 wk following fracture (O–Q); and at 5 wk following fracture (R–T). Images on the left (C, F, I, L, O, and R), at
253, show the entire fracture callus (lines show the proximal and distal aspect of the fracture callus); in the center (D, G, J, M, P, and S) are 1003
magnifications of areas shown in the boxes in the lower-magnification images; and on the right (E, H, K, N, Q, and T), the same images are magnified to
2003.
TCF-dependent transcriptional activity was maintained at a very low level in osteoblasts near the growth plate in normal intact tibia, and there was no
positive staining in cells surrounding the mature bone tissue. Three days following fracture, very weak LacZ (barely detectable) staining was detected in
mesenchymal tissues at the fracture site. Nine days following fracture, positive staining was evident mainly in cells surrounding cartilage matrix and
osteoblasts along the trabeculae and periosteum. Chondrocytes and prehypertrophic chondrocytes also stained at 2 wk after the fracture. Osteoblasts
consistently displayed strong staining signals at 2 and 3 wk following fracture. At the 5 wk time point, LacZ staining occurred mainly in osteoblasts in
the periosteum either next to, or farther away from, the fracture site.
doi:10.1371/journal.pmed.0040249.g001
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Figure 2. b-Catenin Loss- or Gain-of-Function during the Initial Repair Phase Represses Fracture Healing
Ad-Cre and Ad-GFP (control) viruses were injected into fractures of Catnblox(ex3) or Catnbtm2Kem (Cre-null and Cre-Stab, respectively) transgenic mice.
(A) Regulation of b-catenin protein by Cre recombinase-mediated recombination of b-catenin alleles was confirmed by Western blot analysis of the
PLoS Medicine | www.plosmedicine.org July 2007 | Volume 4 | Issue 7 | e2491220
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As shown in Figure 1A, b-catenin protein level is low in
intact bone tissue, but is highly expressed during the entire
period of fracture repair. Data from the human fracture
samples showed a similar pattern (Figure 1B), with high levels
of b-catenin, more than twice that of intact bone, in the
fracture callus 3 wk after the initial fracture, but low levels 3
mo following the initial injury.
Using TCF reporter mice, we observed in which cells b-
catenin mediated TCF-dependent transcription was activated
during the fracture process. In the intact tibia, there was only
weak LacZ staining signal in osteoblasts near the growth plate,
and there was no positive staining in cells surrounding the
mature bone (Figure 1C–1E). At 3 d after the fracture,
undifferentiated ﬁbroblast-like mesenchymal cells ﬁlled the
fracture gap, and there was only small amount of LacZ
staining (Figure 1F–1H).
By 9 d following the fracture, most of the callus was
composed of cartilage. Some cartilage cells exhibited a
hypertrophic phenotype and woven bone was also present.
Cells surrounding the cartilaginous matrix showed strong
LacZ staining. Chondrocytes also displayed staining signal,
and the staining intensity was greatly decreased in prehy-
pertrophic chondrocytes, and no staining was found in
hypertrophic chondrocytes. Osteoblasts along the trabeculae
or periosteum displayed a strong staining intensity (Figure
1I–1K).
The 2 wk post-fracture time point corresponds to the hard
callus stage when hypertrophic cartilage is being actively
replaced by woven bone. Hypertrophic chondrocytes did not
exhibit staining. Osteoblasts either lining the periosteum or
along the islands of woven bone within the provisional callus
also showed strong staining signal. However, the intensity of
staining became fainter as osteoblasts matured to osteocytes
(Figure 1L–1N).
The callus was composed primarily of bone 3 wk after the
fracture, and cartilage was barely detected. LacZ staining was
detected in osteoblasts but there was a very low level of
staining in the fully differentiated osteocytes (Figure 1O–1Q).
The 5 wk post-fracture time point corresponds to the bone
remodeling phase, and the callus was composed of bone
undergoing remodeling. At this time point, LacZ staining was
mainly detected in osteoblasts residing in periosteum both
adjacent to and farther from the fracture site (Figure 1R–1T).
In addition, since background LacZ staining can occur in
wild-type animals, we also performed this staining on wild-
type mice, and we failed to detect positive LacZ staining
signals during fracture healing.
These observations suggest that b-catenin-mediated, TCF-
dependent transcription is activated in both bone and
cartilage formation during fracture healing. In particular,
during endochondral ossiﬁcation, b-catenin signaling is
activated at the early stages of chondrogenesis, but not at
later stages of chondrogenesis (i.e., hypertrophic chondro-
cytes). During osteogenesis, b-catenin is activated in cells with
an osteoblast phenotype, but is down-regulated when
osteoblasts undergo maturation into osteocytes.
Precise Regulation of b-Catenin Signaling Is Required for
Fracture Healing
To determine the role of b-catenin during fracture healing,
we utilized a loss-of-function and gain-of-function approach.
The repair process was observed in Catnbtm2Kem or Catnblox(ex3)
mice, which conditionally express null or stabilized b-catenin
alleles, respectively, when subjected to Cre recombinase
[25,26]. Ad-Cre was injected into the fracture site to promote
the recombination of the conditional alleles. Ad-GFP was
used as a control. Western blot analysis on protein from the
fracture callus showed that treatment with Ad-Cre resulted in
striking regulation of b-catenin expression (Figure 2A). To
study the effect of the virus itself on fracture repair, we
generated tibia fractures in wild-type mice and found no
radiographic or histological difference in the healing
phenotype after injection with either the Ad-Cre or the Ad-
GFP control virus
At 3 wk following fracture, radiographic examination
showed no evidence of bone bridging the fracture site in
Catnbtm2Kem mice treated with Ad-Cre, and there was little new
bone formation (Figure 2B). To our surprise, in the
Catnblox(ex3) mice, in which gene encoding b-catenin was
conditionally stabilized after treatment with Cre recombi-
nase, radiographic analysis also did not show evidence of
bone bridging the fracture site (Figure 2C). Upon histological
examination, fracture sites in Catnbtm2Kem mice mainly
consisted of undifferentiated mesenchymal-like tissues, with
no osteoblasts detected. Catnblox(ex3) mice, however, showed a
surprisingly similar histological appearance to that in
Catnbtm2Kem mice, although less remaining cartilage was
observed (Figure 2E–2J). Histomorphometric measurements
further conﬁrmed the inhibition of bone regeneration in
these two transgenic mice (Figures 2K and S1).
We also observed a signiﬁcant down-regulation of SOX9
and RUNX2 in both of these mice (Figure 2L and 2M). SOX9
is a transcription factor for chondrogenic differentiation,
and is expressed in chondroprogenitors and chondrocytes
[33,34]. RUNX2 is a transcription factor up-regulated during
osteoblast differentiation, and is also expressed by some
hypertrophic chondrocytes [35]. The down-regulation of
these two transcription factors, in agreement with our
histological ﬁndings, suggests a lack of both chondrogenic
and osteogenic differentiation at the fracture sites in these
two transgenic mice.
fracture callus, which was harvested at 3 wk after the fracture. The stabilized mutant b-catenin protein is slightly smaller due to deletion of exon 3.
(B–D) Radiographic analysis from Ad-Cre-treated Catnbtm2Kem mice (B), Ad-Cre-treated Catnblox(ex3) mice (C), and Ad-GFP-treated control mice (D). At 3
wk after fracture, a lack of healing was seen in the mice expressing the null and stabilized alleles. Arrows indicate fracture site.
(E–J) HE staining from Ad-Cre-treated Catnbtm2Kem mice (E and H); Ad-Cre-treated Catnblox(ex3) mice (F and I), and Ad-GFP-treated control mice (G and J).
The fracture sites consisted mainly of undifferentiated mesenchymal-like tissues in mice expressing either the null or stabilized b-catenin alleles, and
there was still less remaining cartilage present in Catnblox(ex3) mice at 3 wk after fracture. Histomorphometric analysis was conducted to analyze bone
regeneration. Photomicrographs in the center row (E, F, and G) are magnified 253; lines show the proximal and distal aspects of the healing fracture
site. Images in the bottom row (H, I, and J) are 1003magnifications of areas shown in the boxes in the lower-magnification images.
(K) Bone volume (BV) is expressed as a percentage of total callus tissue volume (TV).
(L) Western blot of SOX9 at 1 wk and RUNX2 at 3 wk following fracture shows a decrease of both markers in the Cre-null and Cre-stab mice.
(M) Relative expression of SOX9 and RUNX2 were quantified using densitometry;
doi:10.1371/journal.pmed.0040249.g002
PLoS Medicine | www.plosmedicine.org July 2007 | Volume 4 | Issue 7 | e2491221
Beta-Catenin in Fracture Healing
Figure 3. WNT Ligands Regulate b-Catenin during Fracture Healing
(A) Western blot analysis shows expression of DKK1 as detected by an antibody to the His tag.
(B) b-catenin was substantially down-regulated in fractures treated with DKK1.
(C and D) SO staining of fracture samples from DKK1-treated mice (C) and control mice (D) at 1 wk after fracture show that DKK1 treatment down-
regulates chondrogenic differentiation. Images are magnified 253.
(E) Histomorphometric analysis shows a down-regulation of cartilage volume (CV) at 1 wk after fracture, as a percentage of total callus tissue volume
(TV), in DKK1-treated mice.
(F and G) SOX9 was also down-regulated after treatment with Ad-DKK1 at 1 wk following fracture. The expression data are consistent with our
histological findings.
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b-Catenin Is Regulated by WNTs during Fracture Repair
Since b-catenin can be regulated by WNT ligands, we
examined the expression of WNTs and their receptors in the
fracture callus using RT-PCR. Many WNT ligands were
expressed during fracture healing, including WNT4, 5b,
10b, 11 and 13. Furthermore, the receptors FZ1, 2, 4, and 5,
and LRP6 were also up-regulated during fracture healing
(Figure S2). Since WNT4 and WNT10b could mediate
canonical WNT signaling (WNT/b-catenin pathway) [36,37],
it is likely that these WNT ligands are responsible for
activating b-catenin signaling during fracture repair. Fur-
thermore, we also observed an up-regulation of WNT5a and
protein kinase C alpha (PKCa) during fracture repair using
Western blot analysis (Figure S2). Since WNT5a can mediate
WNT/Ca2þ pathway signaling through its mediator PKCa [38],
our results imply that the WNT signaling pathway is complex
during fracture healing, likely involving activation of both
canonical and noncanonical WNT pathways.
To investigate the contribution of WNT ligands to b-
catenin regulation in fracture repair, we used an adenovirus
expressing a His-tagged DKK1, an antagonist of canonical
WNT/b-catenin signaling that inhibits WNT receptor activa-
tion [39,40]. Ad-GFP was also injected into the fracture site as
a control. DKK1 expression was detected by Western blot
analysis using anti-His antibody 1 wk following fracture
(Figure 3A). Callus samples from animals treated with Ad-
DKK1 exhibited a substantial reduction of b-catenin protein
level, as compared to those injected with control virus (Figure
3B), conﬁrming that WNT ligands regulate b-catenin during
fracture repair.
At 1 wk after the fracture, SO staining and histomorpho-
metric analysis showed that almost no cartilage islands were
present in mice treated with DKK1, as compared to control
animals (Figure 3C–3E). SOX9 was also down-regulated after
treatment of Ad-DKK1, suggesting an inhibition of chondro-
genic differentiation after blocking of WNT/b-catenin (Figure
3F and 3G). At 3 wk after the fracture, all of the control
animals showed complete healing, while in DKK1-treated
mice, fractures failed to heal (Figure 3H and 3I). There was a
substantial reduction of both bone and cartilage volume in
DKK1-treated mice, and the fracture site was mainly ﬁlled
with large amount of undifferentiated mesenchymal-like
tissues (Figure 3J–3M). Histomorphometric measurements
conﬁrmed this inhibition of bone formation (Figures 3N and
S1). These phenotypes were nearly identical to the results in
mice expressing Cre-mediated conditional b-catenin null
alleles, suggesting a substantial inhibition of bone healing by
inactivation of the WNT/b-catenin pathway. Furthermore, we
examined the expression of RUNX2 in these mice, and
observed that RUNX2 was expressed at substantially lower
levels in mice expressing DKK1, as compared to control
animals (Figure 3O and 3P).
b-Catenin Plays a Disparate Role in Undifferentiated
Mesenchymal Cells and Cells Committed to the
Osteoblast Lineage
To determine the function of b-catenin in osteoblasts, we
observed fracture healing in mice in which b-catenin loss-of-
function or gain-of-function was restricted to cells commit-
ted to the osteoblast lineage. Mice expressing conditional
alleles were crossed with a1(I)-Cre mice (which restrict Cre
expression to osteoblasts [27]), resulting in mice expressing
the b-catenin null allele in osteoblasts [a1(I)-Catnbnull] or b-
catenin stabilized alleles in osteoblasts [a1(I)-Catnbstab]. A
signiﬁcant increase in bone mass was found in a1(I)-Catnbstab
mutant mice, as previously reported [16]. Western blot
analysis conﬁrmed the expected changes in b-catenin protein
level in the mice (Figure 4A)
At 1 wk following the fracture, a1(I)-Catnbnull mice exhibited
a fracture callus mainly composed of cartilage matrix, while
chondrogenesis was not evident in a1(I)-Catnbstab mice
(unpublished data). Histomorphometric assay conﬁrmed
these histology changes (Figure 4B). At 3 wk after the
fracture, radiographic examination in a1(I)-Catnbnull mice
showed that, although there was some calciﬁed callus present,
the newly formed bone had not completely bridged the
fracture gap, as compared to wild-type mice (Figure 4C and
4E). Radiographic quantiﬁcation conﬁrmed low bone density
in a1(I)-Catnbnull mice, as compared to wild-type mice (Figure
4L). Histological examination showed that the bone ends
were not completely approximated in the a1(I)-Catnbnull mice
(Figure 4F and 4I). Histomorphometric analysis further
showed a signiﬁcant repression of bone regeneration in
a1(I)-Catnbnull mutant mice (Figures 4M and S1).
Surprisingly, radiographic examination in a1(I)-Catnbstab
mice showed enhanced fracture healing, characterized by a
calciﬁed callus bridging the fracture gap as well as an increase
in bone density (Figure 4D and 4E). Radiographic quantiﬁ-
cation, histological studies, and histomorphometric analysis
further revealed that, compared to control animals, a1(I)-
Catnbstab mutant mice showed a larger volume of regenerated
bone tissues within the fracture site (Figures 4G, 4H, 4J, 4K–
4M, and S1).
We also examined expression of SOX9 at 1 wk following
fracture, and observed an up-regulation of this transcription
factor in the a1(I)-Catnbnull mutant mice. However, SOX9 was
down-regulated in a1(I)-Catnbstab mutant animals. Expression
of RUNX2 in these two mice, however, was regulated in the
opposite manner (Figure 4N and 4O).
Since these conditional b-catenin alleles are regulated by a
collagen type I promoter and thus are present in precursor
cells committed to the osteoblast lineage but not in
undifferentiated mesenchymal cells [27], our results support
the concept that early osteoblast lineage cells lacking b-
catenin are blocked in osteoblast differentiation and develop
(H and I) Radiographic analysis from DKK1-treated mice (H) and from control mice (I), at 3 wk after fracture, shows a lack of healing in the DKK1-treated
animals. Arrows indicate fracture site.
(J–M) HE staining from DKK1-treated mice (J and L) and from control mice (K and M) undifferentiated mesenchymal-like cells at the fracture site in DKK1-
treated animals at 3 wk after fracture. Images (J and K) are magnified 253; (L and M) show 1003magnifications of the area shown in the box in the
lower-magnification images.
(N) Assay of bone volume (BV) as a percentage of total callus tissue volume (TV) shows a significant decrease in bone regeneration after DKK1
treatment.
(O and P) RUNX2 was also significantly down-regulated in DKK1-treated mice, suggesting an inhibition of osteoblastic differentiation.
doi:10.1371/journal.pmed.0040249.g003
PLoS Medicine | www.plosmedicine.org July 2007 | Volume 4 | Issue 7 | e2491223
Beta-Catenin in Fracture Healing
Figure 4. b-Catenin Acts to Regulate Bone Formation in Mice Expressing Osteoblast-Specific b-Catenin Null or Stabilized Alleles
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a chondrocyte phenotype instead. Expression of stabilized b-
catenin in cells committed to the osteoblast lineage improves
osteogenesis, thus leading to enhanced fracture healing.
Lithium Treatment Enhances Healing if Started after the
Fracture
Lithium activates b-catenin signaling by inhibiting GSK3b
[41–43]. Also, lithium enhances bone formation and improves
bone mass in mice [31]. To asses the effect of lithium on
fracture repair, treatment was started either 2 wk prior to
initiating the fracture, or 4 d following the fracture in wild-
type mice. Lithium treatment increased the level of b-catenin
in the fracture tissue in both groups (Figure 5A). Mice in
which the lithium treatment was started before the fracture
had reduced bone in the fracture site, while mice in which the
lithium treatment was started late displayed an enhanced
fracture healing with relatively high radiopaque bone density
(Figure 5B–5D). Histological examination of the fracture sites
(Figure 5E and 5F) shows undifferentiated mesenchymal cells
at the fracture site with early lithium treatment, while there is
increased bone volume at the fracture site with late treat-
ment. Radiographic and histomorphometric analysis further
provided evidence that LiCl treatment enhances fracture
healing, but only when utilized after the fracture (Figure 5G
and 5H).
Lithium can have other cellular effects in addition to
inhibiting GSK3b. To determine if lithium is indeed acting
through b-catenin, we gave lithium treatment to Catnbtm2Kem
mice in which the conditional null allele was activated by Ad-
Cre. We found that mice expressing the null allele did not
form as much bone at the fracture site as did wild-type mice
or Catnbtm2Kem mice treated with lithium but not Ad-Cre
(Figure S3), suggesting that lithium acts at least in part
through b-catenin. Although data from the a1(I)-Catnbstab
mice may be confounded by an increased bone density prior
to the fracture, the results from lithium treatment shows that
stabilization of b-catenin through a pharmacologic approach
initiated after the fracture results in a similar enhancement
in bone healing. This suggests that the enhanced bone repair
in a1(I)-Catnbstab mice is due to b-catenin levels in the fracture
healing cells committed to the osteoblast phenotype in the
healing fracture, rather than to the underlying increased
bone mass alone.
Taken together, our results conﬁrm that lithium increases
bone healing through its activation of b-catenin signaling
pathway. These data, therefore, not only support our notion
that b-catenin signaling functions differently at different
stages of fracture repair, but more importantly, raises the
possibility that lithium treatment can be used to enhance
bone repair.
Discussion
In this study, we demonstrated that b-catenin signaling
plays a crucial role in fracture healing. We observed that
precise regulation of b-catenin is important in the early
phases of fracture healing to allow differentiation of
mesenchymal cells into osteoblast and chondrocyte lineages.
Our ﬁndings also indicate that b-catenin plays a disparate
role in undifferentiated mesenchymal cells and in committed
osteoblasts, and as such acts differently during different
phases of fracture repair. These ﬁndings are important not
only for understanding the role of b-catenin in different cell
types, but also has a practical implication for therapy—pre-
fracture lithium treatment inhibits the repair process, but
post-fracture treatment enhanced bone healing. As such,
lithium will enhance fracture healing, but only if started after
cells have become committed to the osteoblast lineage.
During fracture repair, b-catenin-mediated TCF-depend-
ent transcription is not activated in the earliest mesenchymal
tissues present at the fracture site. Once cells that begin to
show phenotypic features of either chondrocyte or osteoblast
precursors, they exhibit b-catenin-mediated TCF-dependent
transcription activity, suggesting a role in the initial phases of
differentiation. In osteoblast lineage cells, b-catenin signaling
activity decreased in later phases of differentiation, as
osteoblasts matured into osteocytes. This ﬁnding is in
agreement with a previous in vitro study, in which van der
Horst and colleagues also observed a down-regulation of b-
catenin signaling during the formation of a mineralized bone
matrix in KS483 cells undergoing late phase osteoblast
differentiation [44], suggesting a similar role for b-catenin
in osteoblasts in fracture healing. During limb development,
b-catenin is expressed in prechondrogenic mesenchymal cells
but is signiﬁcantly decreased in differentiated chondrocytes
[45]. However, in our study, we found that b-catenin-
mediated TCF-dependent transcription was also activated
in chondrocytes and, to a lesser extent, in prehypertrophic
chondrocytes. Thus, the range of activity for b-catenin
mediated TCF-dependent transcription in chondrocytes is
greater in fracture healing than in development, suggesting
that b-catenin plays a role in chondrocytes over a broader
range of differentiation in repair than in development.
Our results showed that many WNT ligands and receptors
are selectively up-regulated during bone healing, several of
which (e.g., WNT4, WNT10b, and LRP6) are known to activate
(A) Western blot analysis shows that b-catenin was regulated in the bone as expected in a1(I)-Catnbnull and a1(I)-Catnbstab (a1(I)-null and a1(I)-stab,
respectively) mice.
(B) Histomorphometric analysis of calluses at 1 wk following fracture, as indicated by cartilage volume (CV) as a percentage of total callus tissue volume
(TV).
(C–E) Radiographic analysis from a1(I)-Catnbnull mice (C), from a1(I)-Catnbstab mice (D), and from wild-type littermate mice (E) at 3 wk after fracture.
Arrows indicate fracture site.
(F–K) HE staining from a1(I)-Catnbnull mice (F and I), from a1(I)-Catnbstab mice (G and J), and from wild-type mice (H and K) shows that bone healing was
inhibited in a1(I)-Catnbnull mice at 3 wk after fracture, with remaining cartilage at the fracture site. a1(I)-Catnbstab mice showed an accelerated fracture
repair with abundant new bone tissue formed. Images (F, G, and H) are 253magnifications; (I, J, and K) are 1003magnifications of the areas shown in
the box in the lower-magnification images.
(L) Relative radiopaque bone density at the fracture site shows decreased bone density in a1(I)-Catnbnull mice and increased bone density in a1(I)-
Catnbstab mice.
(M) Assay of bone volume (BV) as a percentage of total callus tissue volume (TV) shows that a1(I)-Catnbnull mice displayed inhibition of fracture healing,
whereas osteoblast-specific b-catenin activation in a1(I)-Catnbstab mice enhanced bone healing.
(N and O) Regulation of SOX9 at 1 wk and RUNX2 at 3 wk following fracture in a1(I)-Catnbnull, a1(I)-Catnbstab, and wild-type mice.
doi:10.1371/journal.pmed.0040249.g004
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Figure 5. Lithium Treatment Regulates Bone Mass at the Fracture Site
Mice were treated with lithium starting either 2 wk before the fracture (early treatment) or 4 d after the fracture (late treatment).
(A) b-catenin increased 3 wk after fracture in mice receiving either early or late lithium treatment.
(B–D) Radiographic analysis from mice receiving early lithium treatment (B), late lithium treatment (C), or NaCl as a control (D), show that lithium
enhanced fracture healing only when given late. Arrows indicate the fracture site.
(E and F) HE staining from mice receiving early or late lithium treatments, respectively (253). There is immature mesenchymal tissue at the fracture site
in (E), and large amounts of bone in (F).
(G) Relative radiopaque bone density results show that early and late treatment have opposite effects on fracture healing.
(H) Histomorphometric analysis on bone volume (BV) as a percentage of total callus tissue volume (TV), showing that pharmacologic activation of b-
catenin after healing cells become committed to the osteoblast lineage could improve healing, while treatment at earlier time points inhibited fracture
repair.
doi:10.1371/journal.pmed.0040249.g005
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the canonical WNT pathway [36,37]. Moreover, our data
showing that DKK1 treatment inhibits b-catenin signaling
and suppresses fracture repair suggest that the canonical
WNT pathway is the dominant mechanism regulating b-
catenin during bone healing. Since multiple WNT ligands
that activate b-catenin signaling are expressed during the
repair process, there is likely functional redundancy. How-
ever, our results do not exclude the possibility that non-
canonical WNT pathways are also likely activated during
fracture repair, as WNT5a and WNT11 can signal through the
WNT/Ca2þ pathway, which regulates Ca2þ ﬂux and Ca2þ
-sensitive protein kinases and transcription factors, such as
PKCa and calcium/calmodulin-dependent protein kinase II
[38,46]. WNT11 can also activate the c-Jun N-terminal kinase
pathway [47,48]. Indeed, in our study, we not only noticed
that WNT11 was expressed during fracture healing, but also
observed an activation of both WNT5a and its mediator
PKCa. These results suggest that the role for WNT ligands in
fracture repair is complex, potentially involving activation of
multiple pathways (i.e., canonical and noncanonical WNT
pathways).
We observed that b-catenin-mediated TCF-dependent
transcription is activated during both chondrogenesis and
osteogenesis in fracture repair. Mice expressing conditional
b-catenin null alleles after treatment of Cre recombinase
failed to heal, and there was a lack of bone and cartilage at
the fracture site. The histology studies showed immature
mesenchymal cells at the fracture sites. This ﬁnding is not
unexpected given the role of b-catenin during fetal bone
development, in which conditional deﬁciency in early
osteoblast progenitors results in a blockade of osteoblast
differentiation, with immature mesenchymal cells persisting
[49,50]. However, fractures also failed to heal in Catnblox(ex3)
mice whose b-catenin-encoding gene had been stabilized by
treatment with Cre recombinase. The fracture site in this case
was also composed of immature mesenchymal cells, suggest-
ing a block to differentiation. This observation was in stark
contrast to the results from a1(I)-Catnbstab mice, which
expressed osteoblast-speciﬁc stabilized b-catenin alleles; these
mice exhibited signiﬁcantly enhanced bone healing. Thus,
during fracture healing, Cre-mediated conditional b-catenin
stabilization represses differentiation of these mesenchymal
cells, perhaps maintaining these cells in an undifferentiated
proliferative state. Previous in vitro studies and studies of
bone development provide evidence to support this notion,
as WNT signaling activation maintains mesenchymal stem
cells in a less differentiated state during osteogenic differ-
entiation, and stabilization of b-catenin can interfere with the
differentiation of precursors into chondrocytes as well as
osteoblasts during development [49–51]. In cells that have
already adopted an osteoblast phenotype, b-catenin signaling
activation works differently; that is, it promotes osteoblastic
differentiation and enhances osteogenesis. Therefore, the
level of b-catenin needs to be precisely regulated at the
earliest phase of fracture healing to allow for proper
differentiation.
Interestingly, fractures in a1(I)-Catnbnull mice healed with
abundant cartilage matrix at the fracture site, while Catnbtm2-
Kem mice in which conditional b-catenin null alleles were
regulated by Ad-Cre mainly exhibited undifferentiated
mesenchymal-like cells at the fracture site. These data imply
that mesenchymal precursors that have already become
committed to an osteoblast phenotype will adopt a chondro-
blastic phenotype instead if b-catenin is absent. This result
agrees with data from bone development, which show that
osteoblast precursors lacking b-catenin are blocked in
differentiation and develop into chondrocytes instead [49,50].
Our ﬁndings raise the possibility that therapy to activate
b-catenin could be used to enhance fracture repair.
However, since activation of b-catenin signaling inhibits
differentiation of mesenchymal cells not yet committed to
the osteoblastic phenotype, such treatment should be
utilized only after cells are committed to the osteoblast
lineage. One potential therapeutic agent is lithium, which
activates the canonical WNT signaling through inhibition of
GSK3b [41–43], and has demonstrated its capacity to
increase bone formation and improve bone mass in mice
[31]. We found that lithium treatment greatly up-regulates b-
catenin, and indeed has the potential to enhance fracture
healing, but only if started several days after the fracture has
occurred. Since lithium is a pharmacologic agent, and oral
lithium has been used to treat humans with bipolar disease
for over a half-century with substantial beneﬁt [52], its use to
improve bone repair could readily be tested in the clinical
setting.
Supporting Information
Alternative Language Abstract S1. Translation of the Abstract into
Mandarin by Yan Chen
Found at doi:10.1371/journal.pmed.0040249.sd001 (144 KB PDF).
Figure S1. Detailed Histomorphometric Data
For histomorphometric analysis, callus tissues at 3 wk after fracture
were ﬁxed in 4% paraformaldehyde, decalciﬁed in 20% EDTA (pH
7.4), and embedded in parafﬁn. 10 lm sections were prepared and
stained with HE. For each callus, an average of ten tissue sections was
used to determine callus parameters, including trabecular thickness
(lm), trabecular number (per mm), and trabecular separation (lm).
Four animals were analyzed for each group. Data were expressed as
mean 6 standard deviation. Statistical differences were calculated by
using Student t-test. p , 0.001 was considered statistically signiﬁcant
(*p , 0.001).
(A) Trabecular number assay from Ad-Cre-treated Catnbtm2Kem,
Catnblox(ex3), and Ad-GFP-treated control mice.
(B) Trabecular thickness assay from Ad-Cre-treated Catnbtm2Kem,
Catnblox(ex3), and Ad-GFP-treated control mice.
(C) Trabecular separation assay from Ad-Cre-treated Catnbtm2Kem,
Catnblox(ex3), and Ad-GFP-treated control mice.
(D) Trabecular number assay from Ad-DKK1- and Ad-GFP-treated
wild-type mice.
(E) Trabecular thickness assay from Ad-DKK1- and Ad-GFP-treated
wild-type mice.
(F) Trabecular separation assay from Ad-DKK1- and Ad-GFP-treated
wild-type mice.
(G) Trabecular number assay from a1(I)-Catnbnull, a1(I)-Catnbstab, and
wild-type mice.
(H) Trabecular thickness assay from a1(I)-Catnbnull, a1(I)-Catnbstab, and
wild-type mice.
(I) Trabecular separation assay from a1(I)-Catnbnull, a1(I)-Catnbstab, and
wild-type mice.
Found at doi:10.1371/journal.pmed.0040249.sg001 (781 KB PDF).
Figure S2. WNT-Related Gene Expression
At different time points after fracture, calluses were harvested and
total RNA was isolated. Expression of mRNA was compared to that of
the housekeeping control b-2 macroglobin. All experiments were
performed in triplicate. Protein extracts were also isolated, and
Western blot analysis was performed to determine protein expression.
Protein expression was also normalized to GAPDH as a loading control.
(A) Several WNT ligands (WNT4, 5b, 10b, 11, and 13) and receptors
(FZ1, 2, 4, and 5, and LRP6) were activated at mRNA level during
fracture healing.
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(B) Both WNT5a and its signaling mediator PKCa were up-regulated
during fracture repair.
Found at doi:10.1371/journal.pmed.0040249.sg002 (737 KB PDF).
Figure S3. The Effect of Lithium Treatment on Bone Density is
Partially Mediated by b-Catenin
Bone healing was observed 3 wk following generation of a tibia
fracture in mice treated with lithium or control started after creation
of the fracture. There were ﬁve mice in each group. In mice
expressing b-catenin null alleles activated by treatment with Ad-Cre
there was reduced bone mass compared to mice in which Ad-Cre was
not administered or mice in which neither Ad-Cre nor lithium was
administered. An asterisk above the mean indicates a statistically
signiﬁcant difference between b-catenin null and wild-type mice
treated with lithium. Control mice (not treated with lithium) were
assigned an average relative bone density of 1. These data show that
the effect of lithium is at least partially mediated by b-catenin.
Found at doi:10.1371/journal.pmed.0040249.sg003 (2.6 MB PDF).
Table S1. PCR Primer Sequences
Found at doi:10.1371/journal.pmed.0040249.st001 (781 KB PDF).
Table S2. Antibodies Used in This Study
Found at doi:10.1371/journal.pmed.0040249.st002 (781 KB PDF).
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Editors’ Summary
Background. Most people break at least one bone during their life. If the
damaged bone is immobilized with a plaster cast or with metal plates
and pins, most fractures heal naturally and quickly. Soon after a bone is
damaged, cells called pluripotent mesenchymal cells collect at the injury
site. Here, they multiply and change (differentiate) into osteoblasts (cells
that make bone) and chondrocytes (cells that make cartilage, the dense
connective tissue that covers joints). Osteoblasts and chondrocytes
mend the fracture by making new bone, a process called ossification.
Bone healing involves two types of ossification. In intramembranous
ossification, mesenchymal cells and osteoblast progenitor cells make
bone directly, forming a hard ‘‘callus’’ within the fracture. In
endochondral ossification, mesenchymal cells differentiate into chon-
drocytes and make cartilage at the fracture site, which osteoblasts turn
into bone. Finally, the bone made by both types of ossification is
remodeled so that it closely resembles the damaged bone’s original
shape and strength.
Why Was This Study Done? Unfortunately, fractures do not always heal
efficiently. If healing is delayed, additional surgery may be needed to
repair the break. But surgery can be risky, so drug-based ways of
encouraging bone repair would be very useful. To develop such
treatments, researchers need to understand what controls the differ-
entiation and activity of osteoblasts and chondrocytes during normal
healing. In this study, the researchers have investigated the role of the b-
catenin signaling pathway in bone repair. This pathway regulates bone
formation during embryonic development, a process that closely
resembles bone healing. b-catenin is usually degraded rapidly in cells.
However, if a member of a particular family of proteins known as the
WNT family binds to a WNT receptor on the surface of a cell, b-catenin
moves into the cell’s nucleus where it interacts with a protein called T
cell factor (TCF). This interaction activates the transcription (the copying
of DNA into messenger RNA, which is used to make proteins) of
numerous genes and alters the behavior of the cell.
What Did the Researchers Do and Find? The researchers first measured
b-catenin levels in mouse and human bones. In both species, much more
b-catenin was made in bones undergoing repair than in intact bones.
Then they studied TCF reporter mice—animals in which TCF controls the
expression of a marker gene. b-catenin-mediated TCF-dependent tran-
scription, they report, was activated during both bone and cartilage
formation after a fracture in these mice. Next, the researchers made mice
that could be induced to express an inactive form of b-catenin or a
stabilized (permanently active) form of b-catenin in all the cells in a bone
fracture. Expression of inactive b-catenin slowed the rate of healing but,
unexpectedly, so did expression of stabilized b-catenin. Osteoblast-
specific expression of inactive b-catenin also delayed bone healing,
whereas osteoblast-specific expression of stabilized b-catenin enhanced
the process. Finally, treatment of wild-type mice with lithium (which
prevents the degradation of b-catenin) enhanced bone healing if given
after a fracture, but interfered with it if given before.
What Do These Findings Mean? These findings indicate that b-catenin
signaling (which, the researchers show, is mainly activated by WNT
signaling) has different effects at different stages of bone repair. Early in
the process, it controls the ratio of osteoblasts and chondrocytes made
from the pluripotent mesenchymal cells. Consequently, too much or too
little b-catenin interferes with bone healing at this stage. Later on, b-
catenin promotes the differentiation of osteoblasts and enhances their
ability to make bone, and so too little b-catenin at this stage prevents
healing, whereas increased b-catenin levels stimulate healing. These
findings need to be confirmed in people before testing agents that affect
b-catenin signaling for their effects on human bone healing. Never-
theless, the researchers’ final discovery that lithium improves bone
healing if given at the right time is particularly encouraging; lithium is
widely used to treat one form of depression so could be readily tested in
clinical trials.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040249.
 MedlinePlus encyclopedia contains pages on broken bones and on
bone fracture repair (in English and Spanish)
 Wikipedia has pages on bone fracture and on bone healing (note:
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
 The UK National Health Service Direct encyclopedia provides pages on
broken bones
 Animations of intramembranous and endochondral ossification are
available from the Ministry of Advanced Education, Training and
Technology, Province of British Columbia, Canada
 The American Academy of Orthopedic Surgeons has an informative
discussion of fractures
 The Hospital for Sick Children in Toronto (where the authors of this
study are affiliated) has a Web site called SickKids, which contains a
page on child physiology, including diagrams of bone development
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